缬沙坦/氢氯噻嗪复方制剂和缬沙坦降压疗效的比较

中国临床药理学与治疗学 ›› 2008, Vol. 13 ›› Issue (10): 1177-1181.

缬沙坦/氢氯噻嗪复方制剂和缬沙坦降压疗效的比较

曹东平, 吕军娥, 刘永欣, 姚文静, 容春莉, 于薇

河北省人民医院心脏中心, 石家庄 050051, 河北

收稿日期:2008-07-21 修回日期:2008-09-22 出版日期:2008-10-26 发布日期:2020-10-19
作者简介:曹东平, 女, 副主任医师, 副教授, 研究方向:高血压病。Tel:0311-85988645 　 E-mail:cdpsyy @sina.com

Comparison of valsartan/hydrochlorothiazide and valsartan in the treatment of hypertension

CAO Dong-ping, LV Jun-e, LIU Yong-xin, YAO Wen-jing, RONG Chun-li, YU Wei

Heart Center of the People' sHospital of Hebei Province, Shijiazhuang 050051, Hebei, China

Received:2008-07-21 Revised:2008-09-22 Online:2008-10-26 Published:2020-10-19

摘要/Abstract

摘要： 目的: 对比缬沙坦/氢氯噻嗪(缬沙坦80 mg/氢氯噻嗪 12.5 mg) 复方制剂与缬沙坦(缬沙坦 80 mg) 治疗轻、中度原发性高血压的谷峰比值(TPR) 和平滑指数(SI) , 评价缬沙坦氢氯噻嗪的降压疗效。方法: 选择轻、中度原发性高血压病患者[SBP ≥140 mm Hg 且 <160 mm Hg(1 mm Hg=0.133 kPa) , DBP ≥95 mm Hg并且 <110 mm Hg]84 例, 随机分为缬沙坦/氢氯噻嗪和缬沙坦组, 共服药 8 周, 观察服药前后血压及生化指标的变化。结果: 治疗 8 周后, 缬沙坦/氢氯噻嗪组和缬沙坦组降压有效率分别为 84.2%、52.5%, 达标率分别为 73.9%、42.9%, 两组间差异有统计学意义(P <0.001) 。缬沙坦/氢氯噻嗪组 TPR 为 SBP76.7%、DBP 71.2%, 均 >50%;SI 为 SBP 1.14 ±0.39、DBP 1.09 ±0.27, 均 >1。缬沙坦组的 TPR为 SBP 77.6%、DBP 71.3%, 均 >50%;SI 为 SBP1.24±0.39、DBP 1.19±0.27, 均>1。两组的 TPR和SI 差别无统计学意义(P>0.05) 。结论: 缬沙坦 80 mg/氢氯噻嗪 12.5 mg 复方制剂治疗轻中度原发性高血压患者疗效优于单用缬沙坦 80 mg,TPR 和SI 无显著差别。

关键词: 缬沙坦/氢氯噻嗪, 缬沙坦, 原发性高血压, 平滑指数, 谷峰比值

Abstract: AIM: To compare the T/P ratio and the smoothness index of blood pressure in the treatment of mild to moderate essential hypertension with fixed-dose valsartan/hydrochlorothiazide (80/12.5 mg) and valsartan (80 mg) , and to evaluate the depressurization therapeutic effect of valsartan/hydrochlorothiazide (80/12.5 mg) .METHODS: 84 patients with mild to moderate essential hypertension(SBP≥140 mm Hg and <160 mm Hg, DBP ≥95 mm Hg and <110 mm Hg) had been divided into randomly valsartan hydrochlorothiazide group and valsartan group.The treatment lasted for 8 weeks and the changes of blood pressure and biochemical indicator were observed be-fore and after treatment .RESULTS: The effective rate of depressurization in valsartan/hydrochlorothiazide group and valsartan group were 84.2% , 52.5% re-spectively .The rate of patient reaching goal BP levels were 73.9%, 42.9%respectively .There was statisti-cally significant difference between the two groups(P < 0.001) .The T/P ratio of SBP was 76.7%, the DBP was 71.2%in valsartan/hydrochlorothiazide group, the smoothness index of SBP was 1.14 ±0 .39, the DBP was 1.09±0 .27.The T/P ratio of SBP was 77.6%, the DBP was 71.3%, The smoothness index of SBP was 1.24 ±0.39, the DBP was 1.19 ±0.27.There were no significant difference (P>0.05) between the T/P ratio and smoothness index in the both groups. CONCLUSION: The efficacy of fixed-dose Valsartan Hydrochlorothiazide (80/12.5 mg) was superior to val-sartan(80 mg) monotherapy in the treatment of mild to moderate essential hypertension.

Key words: valsartan/hydrochlorothiazide, valsar-tan, essential hypertension, smoothness index, T/Pratio

中图分类号:

R544.1

曹东平, 吕军娥, 刘永欣, 姚文静, 容春莉, 于薇. 缬沙坦/氢氯噻嗪复方制剂和缬沙坦降压疗效的比较[J]. 中国临床药理学与治疗学, 2008, 13(10): 1177-1181.

CAO Dong-ping, LV Jun-e, LIU Yong-xin, YAO Wen-jing, RONG Chun-li, YU Wei. Comparison of valsartan/hydrochlorothiazide and valsartan in the treatment of hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(10): 1177-1181.

参考文献

[1] 何清, 曾群英 .缬沙坦治疗中度高血压的临床研究[J] .国外医学·心血管分册, 2000, 27(6) :353-355.
[2] Plat F, Saini R.Management of hypertension:the role com-bina-tion therapy[J] .Am J Hypertens, 1997, 10( Suppl) :262-271.
[3] 郑勇 .缬沙坦治疗原发性高血压动态血压分析[J] .河南大学学报 :医学科学版, 2003, 22( 2) :38-39.
[4] 林金秀, 吴可贵.1999 年世界卫生组织国际高血压联盟关于高血压治疗指南[J] .高血压杂志, 1999, 7( 2) :97-110.
[5] 陈新谦, 金有豫, 汤光.新编药物学[M] .15版.北京:人民卫生出版社, 2003:373-374.
[6] 沈国强, 周文君.缬沙坦氢氯噻嗪联合治疗原发性老年人高血压临床疗效观察[J] .临床医学, 2003,23( 12) :49.
[7] 邓兴臣, 冯愉态.依那普利小剂量双氢克尿噻治疗高血压病 61 例[J] .山东医药, 2000, 40(22) :48.
[8] Anderson RJ, Duchin KL, Gore RD, et al.Once-daily fosi-nopril in the treatment of hypertension[J] .Hypertension,1991, 17(5) :636-642.
[9] Ford NF, Fulmor IE, Nichola PS, et al.Fosinopril mono-therapy:relationship between blood pressure reduction and time of administration[J] .Clin Cardiol, 1993, 16(4) :324-330.
[10] Sica DA, Culter RE, Parmer RJ.Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril, and enala-pril in patients with chronic renal insufficiency[J] .Clin Pharmacokinet, 1991, 20(5) :420-427.
[11] Tsunoda K, Abe K, Hagino T, et al.Hypotenshe effect of losartan, a nonpeptide angiotensinⅡ receptor antagonist,in essential hypertension[J] .Am J Hypertens, 1993, 6(1) :28-32.
[12] Munafo A.Drug concentration response relationships in normal volun-teers after oral administration of losartan, an angiotensinⅡ receptor an-tagonist[J] .Clin Pharmacol Ther, 1992, 51(5) :513-521.

[1]	杨胜, 王德国. 沙库巴曲缬沙坦联合达格列净治疗射血分数减低型心力衰竭疗效及对血清cTnⅠ、BNP水平的影响[J]. 中国临床药理学与治疗学, 2022, 27(9): 1010-1015.
[2]	蒯铮, 张潇伊, 邹云增. 血管紧张素受体脑啡肽酶抑制剂在老年高血压中的应用[J]. 中国临床药理学与治疗学, 2022, 27(4): 442-445.
[3]	范剑峰，方译，郑春华. 沙库巴曲缬沙坦钠治疗慢性心力衰竭患者的临床疗效分析[J]. 中国临床药理学与治疗学, 2019, 24(7): 810-814.
[4]	魏子寒，李栋博，元峥，陆颍，杨国杰. 沙库巴曲缬沙坦治疗左心疾病相关性肺动脉高压的临床研究[J]. 中国临床药理学与治疗学, 2019, 24(1): 57-62.
[5]	金岳龙，王林红，朱丽君，梁伟，段滢,杨松，陈燕春，赵祥海，沈冲，姚应水. 一氧化氮合酶基因多态性与常用降压药疗效的关联研究[J]. 中国临床药理学与治疗学, 2017, 22(5): 538-544.
[6]	雍小兰，冯仕银，李楠，黄娟，王蓝天，康辉. 磷酸瑞格列汀和缬沙坦在健康人体的药代动力学相互作用研究[J]. 中国临床药理学与治疗学, 2016, 21(6): 661-666.
[7]	郭道遐, 陈燕春, 王林红, 鲁玮, 沈冲, 杨松, 赵祥海, 金岳龙, 姚应水. 高迁移率族蛋白1基因多态性与中国南方农村常用高血压药物疗效的关系[J]. 中国临床药理学与治疗学, 2014, 19(7): 766-771.
[8]	尹芳, 李云飞, 黄继汉, 李禄金, 郑青山. 长效降压药动态血压试验设计与定量分析方法实例介绍[J]. 中国临床药理学与治疗学, 2012, 17(6): 666-671.
[9]	李刚强, 阎伟, 巢胜吾, 樊济海. 原发性高血压患者中血管紧张素Ⅱ2型受体基因A1675G多态性与缬沙坦降压疗效的相关性研究[J]. 中国临床药理学与治疗学, 2012, 17(2): 185-188.
[10]	徐承华, 杨玉雯, 曹蘅. β₁肾上腺素受体与CYP2D6基因多态性对美托洛尔抗高血压治疗的影响[J]. 中国临床药理学与治疗学, 2011, 16(12): 1414-1418.
[11]	彭翠英, 周翠兰, 贺庆芝. 湖南汉族人群TNF-α基因-308G/A多态与原发性高血压相关性研究[J]. 中国临床药理学与治疗学, 2011, 16(1): 57-60.
[12]	李玲, 谭志荣, 陈尧, 周淦, 郭栋, 严谨, 阳国平, 欧阳冬生. 快速灵敏的LC-MS/MS法测定人血浆中缬沙坦浓度[J]. 中国临床药理学与治疗学, 2010, 15(7): 809-813.
[13]	吴小冬, 张道友, 崔明春, 杨利才, 杨沿浪, 朱新俭. 缬沙坦与氟伐他汀单用及联用对阿霉素肾病大鼠血清肝细胞生长因子的影响[J]. 中国临床药理学与治疗学, 2010, 15(3): 305-309.
[14]	王新, 杨玉雯, 王安才, 孔祥权. 缬沙坦干预对缺氧性肺动脉高压大鼠大电导钙激活钾通道的影响[J]. 中国临床药理学与治疗学, 2009, 14(9): 1032-1035.
[15]	曹东平, 彭应心, 姚文静, 容春莉, 于薇, 乔淑章. 缬沙坦-氢氯噻嗪合用治疗高血压早期肾损害的疗效[J]. 中国临床药理学与治疗学, 2009, 14(5): 567-571.